SecBot SecBot
8-K ·Filed May 4, 2026

BCRX

BIOCRYST PHARMACEUTICALS INC
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001171843-26-002960
8-K context-dependent: Items 7.01
Actionable Insight ▲ Bullish

The $70M upfront provides immediate cash runway and validates navenibart's commercial potential. Monitor Phase 3 data readouts and milestone triggers (regulatory filings) for further upside. The partnership reduces European commercial risk.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$9.20
T+0 close · May 4, 2026 · via day close
Latest settled
+3.59%
T+60 · $9.53
Vs SPY
+1.73%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 4 $9.20entry
  2. T+1 · 7mo ago −1.85%α −2.64% · $9.03
  3. T+5 · 6mo ago −6.74%α −9.68% · $8.58
  4. T+20 · 6mo ago −6.85%α −12.49% · $8.57
  5. T+60 · 4mo ago +3.59%α +1.73% · $9.53

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioCryst entered a European licensing agreement for navenibart (HAE) with Neopharmed Gentili, receiving $70M upfront and up to $275M in milestones plus tiered royalties (18-30%). The deal strengthens the balance sheet and provides non-dilutive capital while retaining significant upside. Phase 3 remains on track for US filing by end-2027.

Key Facts

  • $70 million upfront payment
  • Up to $275 million in future regulatory and sales milestone payments
  • Tiered royalties on net sales ranging from 18% to 30%
  • Neopharmed Gentili gains exclusive European commercialization rights
  • Navenibart Phase 3 program on track for US regulatory filing by end of 2027
  • Builds on prior 2025 agreement for ORLADEYO European business sale

Financial Impact

Upfront $70M cash infusion, potential total deal value up to $345M including milestones, plus ongoing royalties (18-30%)

cashrevenue (future)royalty income

Risk Factors

  • Clinical trial failure or regulatory delays for navenibart
  • Milestone and royalty payments depend on approval and commercial success
  • Partner execution risk in European market
  • Potential dilution if future capital needs exceed expectations

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001171843-26-002960
Exhibit: exh_991.htm0001171843-26-002960
Document: 0001171843-26-002960-index-headers.html0001171843-26-002960
Document: 0001171843-26-002960-index.html0001171843-26-002960
Document: 0001171843-26-002960.txt0001171843-26-002960

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 4, 2026